VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

The purpose of the trial is to evaluate the safety and efficacy of a new antifungal with a novel mechanism of action in immunocompromised adults with invasive aspergillosis.

Inclusion Criteria

Acute Leukemia (AML or ALL) patient or allo-HCT recipient with a diagnosis of IA

Exclusion Criteria

Pregnant or breastfeeding
IA involving sites other than lungs and sinuses
Graft failure, acute or extensive chronic GvHD
Uncontrolled diabetes

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03327727.

To compare the safety and efficacy of VL-2397 to standard first-line treatment for

invasive aspergillosis in immunocompromised adults with acute leukemia or recipients of

an allogeneic hematopoietic cell transplant (allo-HCT).

Trial PhasePhase II

Trial Typetreatment

Lead OrganizationVical Inc

Primary IDVL2397-201
Secondary IDsNCI-2018-01346, 2017-003435-11
ClinicalTrials.gov IDNCT03327727

VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

Inclusion Criteria

Exclusion Criteria

Have a question?
We're here to help

Which trials are right for you?

VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

Description

Eligibility Criteria

Locations & Contacts

Trial Objectives and Outline

Trial Phase & Type

Lead Organization

Trial IDs

Have a question?We're here to help

Which trials are right for you?

Have a question?
We're here to help